BrightPath Biotherapeutics Co.,Ltd. [4594.T]
TOKYO, Jun 26 (Pulse News Wire) – Brightpath Biotherapeutics CO.,LTD. (4594.T) outlined its strategic plans and growth potential, forecasting revenue growth through 2030.
The company reported capital of ¥2.574 billion as of March 2026 and highlighted advancements in its cancer immunotherapy pipeline, including the initiation of clinical trials for BCMA CAR-iPSNKT (BP2,202) in the United States and ongoing trials for HER2 CAR-T (BP2,301). BrightPath expects to commence Phase I clinical trials for iPS BCMA CAR-NKT in 2026 targeting multiple myeloma across multiple US sites. The firm also detailed its research and development expenses, noting an increase due to faster progress in some projects compared to initial timelines.
For fiscal year 2027, the company forecasts sales of 1,295 million yen, operating profit of 1,947 million yen, ordinary profit of 1,949 million yen, and net income of 1,680 million yen, representing a significant rise from previous years. In addition, BrightPath emphasized its strategy to enhance investor relations activities, planning quarterly earnings releases and annual shareholder meetings with enhanced English-language communications aimed at overseas investors. The company's focus remains on leveraging partnerships and licensing agreements to expedite development cycles while maintaining robust internal pipelines.
🟢 Confidence: High AI-translated content.